Xylocaine spray for anal cancer pain

Bottom line: There is no direct evidence in the supplied literature that topical lidocaine (Xylocaine) spray improves cancer-related anal pain in adults with anal cancer, nor evidence comparing it with systemic cancer-pain regimens. NICE CKS

Lidocaine has a local anaesthetic action and can relieve pain and discomfort at the application site, so it is biologically plausible as a short-term adjunct for focal anal/perianal pain. SmPC Anodesyn

However, topical local anaesthetics have a relatively short duration of action and do not provide continuous relief through the day; this limitation is likely to be particularly important for persistent tumour-related, treatment-related, or defaecation-associated anal pain. NICE CKS

Clinical position: Treat topical lidocaine spray as a brief, local rescue measure rather than stand-alone analgesia for cancer-related anal pain. NICE CKS

• For mild-to-moderate local pain, topical non-opioid analgesia may be used symptomatically when treatment of the underlying cause is not possible or insufficient. NICE CKS
• For moderate-to-severe pain, combine topical treatment with systemic analgesia rather than relying on topical therapy alone. NICE CKS
• For severe cancer-related mucosal pain, specialist practice may include topical opioids, but systemic opioids are usually required when pain is severe or difficult to control. NICE CKS
• Oral oxycodone and morphine are reasonable first-line strong-opioid options for adult cancer pain, with low-certainty evidence suggesting little or no clinically important difference in analgesia or overall adverse effects between them. Schmidt-Hansen et al. 2022

Evidence from a cancer-pain Cochrane review therefore supports selecting and titrating a systemic strong opioid according to the individual’s response and tolerability, rather than expecting a topical anaesthetic spray to control ongoing cancer pain. Schmidt-Hansen et al. 2022

Safety: Anal topical preparations containing local anaesthetics may reduce pain, burning and itching but can sensitise anal skin; lidocaine is preferred over tetracaine, cinchocaine and pramocaine because those alternatives are more irritant. NICE CKS

Exclude local infection, such as herpes simplex or perianal thrush, before topical anal treatment, because this may alter management and topical preparations may be inappropriate. NICE CKS

With repeated or prolonged application to damaged irradiated, ulcerated, or tumour-involved mucosa, use the minimum effective amount and review benefit frequently, because the available context does not establish safety or dosing for lidocaine spray in anal-cancer mucosal disease. NICE CKS

Comparison with other local strategies: Haemorrhoidal topical preparations have no evidence that one preparation is more effective than another, although this evidence does not address malignant anal pain. NICE CKS

Topical corticosteroid-containing products may reduce inflammation and pain but prolonged use can cause skin atrophy, contact dermatitis and sensitisation, making them unsuitable as an empiric long-term substitute for cancer-pain management. NICE CKS

Glyceryl trinitrate rectal ointment has modest analgesic benefit in chronic anal fissure through internal anal-sphincter relaxation, but this is a fissure-specific mechanism and should not be extrapolated as treatment for anal-cancer pain unless coexistent fissure or sphincter spasm is suspected. SmPC Rectogesic

Pragmatic GP approach: Clarify whether the dominant driver is tumour ulceration, radiotherapy/chemoradiotherapy mucositis or dermatitis, fissure/spasm, constipation and painful defaecation, infection, or neuropathic pain, and address reversible contributors alongside analgesic escalation. NICE CKS

Consider a carefully supervised trial of lidocaine spray for discrete breakthrough pain, for example before bowel motions or local care, while ensuring an adequate systemic analgesic plan for background pain and involving oncology or specialist palliative care when pain remains difficult to manage. NICE CKS